Abstract:Background: Although conventional pain relief therapeutics have centered around mu-opioid agonists, these drugs are limited by adverse side effects, including respiratory depression and addiction potential. The ongoing opioid epidemic has galvanized research into novel analgesic therapies with more favorable profiles. New pharmacologic agents have been developed to target neuronal pathways involved in pain sensation. Certain receptors have been recognized to mediate nociceptive transmission, central sensitization, and the development of chronic pain states. Objectives: We conducted a literature review to identify potential targets for novel analgesic therapies. Study design: This study is a narrative review of potential analgesic targets. We characterize their antinociceptive mechanisms of action and evaluate their therapeutic potential. Methods: A systemized search of available literature on novel analgesics was performed. A search was performed through the PubMed database to identify articles with key words of "novel analgesics," "novel non-opioid analgesics," "novel pain targets," and "non-opioid analgesics." Potential drug classes were identified and researched through corresponding keywords, with an emphasis on publications from 2018 to 2020. Older articles were included if frequently referenced by current literature. Results: Potential novel analgesic targets include Nav1.7, Nav1.8, CaV2.2, and transient receptor potential vanilloid-1 (TRPV1) cation channel receptors in the peripheral nervous system. Other approaches disrupt the synthesis of pronociceptive signaling molecules such as nitric oxide, prostaglandin E2, and interleukin-6 (IL-6). Within central pain pathways, modification of kappa-opioid, delta-opioid, N-methyl-D-aspartate, and cannabinoid receptors have been investigated in chronic pain and hyperalgesia models. Recent advances in molecular technology have also presented opportunities to modify protein expression or the cellular genome altogether. Limitations: Several analgesic targets have only demonstrated efficacy in preclinical trials. There are limited data evaluating the long-term safety profiles of therapies further on in development. Conclusions: We provide an overview of potential analgesic therapies in various stages of development, which may become clinically relevant in the near future. Some drugs such as TRPV1 agonists, anti-IL-6, and anti-nerve growth factor antibodies have demonstrated analgesic effect in specific clinical pain states.

The IBS bug-pain connection

Pharmacological Approach for Managing Pain in Irritable Bowel Syndrome: A Review Article

Targeting the endocannabinoid system for the treatment of abdominal pain in irritable bowel syndrome

Importance of Non-pharmacological Approaches for Treating Irritable Bowel Syndrome: Mechanisms and Clinical Relevance

Stimulating the development of mechanism-based, individualized pain therapies

Opioid analgesia: recent developments

Chronic abdominal pain in irritable bowel syndrome – current and future therapies

Pain: recognizing the power of non-pharmaceutical interventions

Mast cell modulation: A novel therapeutic strategy for abdominal pain in irritable bowel syndrome

Emerging innovation in pain medicines

Pain Severity Correlates With Biopsy-Mediated Colonic Afferent Activation But Not Psychological Scores in Patients With IBS-D

Advances in the pathological mechanisms and clinical treatments of chronic visceral pain

Improving Preclinical Development of Novel Interventions to Treat Pain: Insanity Is Doing the Same Thing Over and Over and Expecting Different Results

Diminished neurokinin-1 receptor availability in patients with two forms of chronic visceral pain

Viscerosomatic facilitation in a subset of IBS patients, an effect mediated by N-methyl-D-aspartate receptors

A History of Pain Research

A Pharmacological Rationale to Reduce the Incidence of Opioid Induced Tolerance and Hyperalgesia: A Review

Receptor and Molecular Targets for the Development of Novel Opioid and Non-Opioid Analgesic Therapies

From taboo to treatment: The emergence of psychedelics in the management of pain and opioid use disorder

Preface to the special issue "Pain"

Pharmacological treatment of pain among persons with opioid addiction: A systematic review and meta‐analysis with implications for drug development